drugset / Trial / NCT00438113

Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF

NCT00438113

RandomizedParallel-groupOpen-labelPrevention

Summary

Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in numerous hospitalizations. Catheter ablation is a technique that has evolved significantly to improve symptomatic recurrences, but does not offer a 100% cure rate. We hypothesize that the use of aggressive BP lowering will reduce the rate of recurrent AF after catheter ablation for AF. We plan a randomized clinical trial of aggressive BP lowering versus standard BP control to investigate this.

Timeline

Start
2009-12
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 10 mg Oral
Comparator Atenolol Other / unclassified 50 mg Oral
Comparator Hydrochlorothiazide Unknown 12.5 mg Oral
Comparator Quinapril Small molecule 40 mg Oral
Comparator Terazosin Small molecule 1 mg Oral

Indications